146 related articles for article (PubMed ID: 37771433)
1. Editorial: Treatment for advanced breast cancer with brain metastases.
Yan M; Yang J
Front Oncol; 2023; 13():1268702. PubMed ID: 37771433
[No Abstract] [Full Text] [Related]
2. Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis.
Huo X; Shen G; Wang T; Li J; Xie Q; Liu Z; Wang M; Zhao F; Ren D; Zhao J
Front Oncol; 2023; 13():1003565. PubMed ID: 36890831
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Duchnowska R; Loibl S; Jassem J
Cancer Treat Rev; 2018 Jun; 67():71-77. PubMed ID: 29772459
[TBL] [Abstract][Full Text] [Related]
4. Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.
Nounou MI; Adkins CE; Rubinchik E; Terrell-Hall TB; Afroz M; Vitalis T; Gabathuler R; Tian MM; Lockman PR
Pharm Res; 2016 Dec; 33(12):2930-2942. PubMed ID: 27528392
[TBL] [Abstract][Full Text] [Related]
5. Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates.
Albarrán V; Rosero DI; Chamorro J; Pozas J; San Román M; Barrill AM; Alía V; Sotoca P; Guerrero P; Calvo JC; Orejana I; Pérez de Aguado P; Gajate P
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293515
[TBL] [Abstract][Full Text] [Related]
6. Apatinib combined with trastuzumab and albumin-bound paclitaxel for treatment of HER2+ breast cancer with brain metastases resistant to anti-HER2 TKIs: A case report.
Huang J; Chen X; Guo J; Song L; Mu Y; Zhao H; Du C
Oncol Lett; 2023 Feb; 25(2):56. PubMed ID: 36644147
[TBL] [Abstract][Full Text] [Related]
7. HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer.
Olson D; Taylor J; Willis K; Hensley K; Allred S; Zaval M; Farr L; Thurman R; Jain N; Hein R; Ulrich M; Peterson S; Kulukian A
Cancer Res Commun; 2023 Sep; 3(9):1927-1939. PubMed ID: 37721518
[TBL] [Abstract][Full Text] [Related]
8. Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy.
Niwinska A; Pogoda K; Jagiello-Gruszfeld A; Duchnowska R
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205723
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic agents in the management of brain metastases.
Venur VA; Ahluwalia MS
Curr Opin Oncol; 2017 Sep; 29(5):395-399. PubMed ID: 28787285
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
11. Research trends and prospects on brain metastasis from breast cancer: A bibliometric analysis.
Wu SQ; Liu Y; Zhou J; You YT; Zhou XH; Chen LQ; Kwan HY; Zhao XS; Wu YF; Liu YY
Front Oncol; 2023; 13():1091249. PubMed ID: 37091185
[TBL] [Abstract][Full Text] [Related]
12. Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer.
Aapro M; Cardoso F; Curigliano G; Eniu A; Gligorov J; Harbeck N; Mueller A; Pagani O; Paluch-Shimon S; Senkus E; Thürlimann B; Zaman K
Breast; 2022 Dec; 66():145-156. PubMed ID: 36279803
[TBL] [Abstract][Full Text] [Related]
13. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
14. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
Awada G; Gombos A; Aftimos P; Awada A
Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
[TBL] [Abstract][Full Text] [Related]
16. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
Kim LS; Huang S; Lu W; Lev DC; Price JE
Clin Exp Metastasis; 2004; 21(2):107-18. PubMed ID: 15168728
[TBL] [Abstract][Full Text] [Related]
18. Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer.
Epaillard N; Bassil J; Pistilli B
Cancer Treat Rev; 2023 Sep; 119():102597. PubMed ID: 37454577
[TBL] [Abstract][Full Text] [Related]
19. Targeted treatment of advanced and metastaticbreast cancer with lapatinib.
Corkery B; O'Donovan N; Crown J
Onco Targets Ther; 2008 Sep; 1():21-34. PubMed ID: 21127749
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]